

Pneumococcal Antibody Panel (23 Serotype)

 Order Name: **PNEUMO 23**
 Test Number: 5575605
 Revision Date: 01/01/2025

TEST NAME	METHODOLOGY	LOINC CODE
Pneumococcal Antibody Panel (23 Serotype)	Fluoroimmunoassay	

SPECIMEN REQUIREMENTS

Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	1.0 mL (0.5 mL)	Serum	Clot Activator SST	Room Temperature
Instructions	<p>Notes: 0.5 mL (Note: This volume Does NOT allow for repeat testing). Specimen Type: Gel-barrier tube Specimen Storage: Maintain specimen at room temperature. Specimen Collection: Not Available Special Instructions: Testing referred to Eurofins Viracor LLC EURKS#401835 Specimen Stability: Ambient: 1 week, Refrigerated : 1 week, Frozen: 5 months</p>			

GENERAL INFORMATION

Expected TAT	7-10 Days
Clinical Use	<p>Includes Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. (Conjugated Serotypes: 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.).</p> <p>A pre-and post-vaccination sample comparison is required in order to assess the humoral immune response to vaccination with Streptococcus pneumoniae vaccine. Post vaccination samples should be obtained at 4 weeks post-immunization. A single sample provides only general immune status of an individual to various serotypes of pneumococci. Immune response to pneumococci may vary in different individuals based on the age, vaccination status, immunologic competence and the serotype of the organism. Long-term protection is generally considered to be a serotype antibody level of 1.3 ug/ mL or greater.</p> <p>Following vaccination, an antibody ratio of less than twofold is considered a non-responder; a ratio of two-to fourfold is a weak responder; a ratio of fourfold or greater is a good responder. The higher the pre-vaccination antibody level for a specific pneumococcal serotype, the less likely the response will increase significantly after vaccination.</p> <p>An increased antibody level to 50-70 percent or more of the serotypes is thought to represent a normal humoral response. In the case of pure polysaccharide vaccine, indication of immune system competence is further delineated as an adequate response to at least 70 percent of the serotypes in the vaccine challenge for those 6-65 years of age, or to at least 50 percent of the serotypes in the vaccine challenge for those 2-5 years of age.</p>
CPT Code(s)	86581
Service Provided By	